Lamerato-Kozicki AR, Helm KM, Jubala CM, Cutter GC, Modiano JF. Canine hemangiosarcoma originates from hematopoietic precursors with potential for endothelial differentiation. Exp Hematol. 2006;34(7):870–8.
Article
CAS
PubMed
Google Scholar
Tamburini BA, Phang TL, Fosmire SP, Scott MC, Trapp SC, Duckett MM, Robinson SR, Slansky JE, Sharkey LC, Cutter GR, et al. Gene expression profiling identifies inflammation and angiogenesis as distinguishing features of canine hemangiosarcoma. BMC Cancer. 2010;10:619.
Article
CAS
PubMed
PubMed Central
Google Scholar
Kim JH, Graef AJ, Dickerson EB, Modiano JF. Pathobiology of Hemangiosarcoma in Dogs: Research Advances and Future Perspectives. Vet Sci. 2015;2(4):388–405.
Article
PubMed
PubMed Central
Google Scholar
Brown NO, Patnaik AK, MacEwen EG. Canine hemangiosarcoma: retrospective analysis of 104 cases. J Am Vet Med Assoc. 1985;186(1):56–8.
CAS
PubMed
Google Scholar
Batschinski K, Nobre A, Vargas-Mendez E, Tedardi MV, Cirillo J, Cestari G, Ubukata R, Dagli MLZ. Canine visceral hemangiosarcoma treated with surgery alone or surgery and doxorubicin: 37 cases (2005–2014). Can Vet J. 2018;59(9):967–72.
PubMed
PubMed Central
Google Scholar
Wood CA, Moore AS, Gliatto JM, Ablin LA, Berg RJ, Rand WM. Prognosis for dogs with stage I or II splenic hemangiosarcoma treated by splenectomy alone: 32 cases (1991–1993). J Am Anim Hosp Assoc. 1998;34(5):417–21.
Article
CAS
PubMed
Google Scholar
Prymak C, McKee LJ, Goldschmidt MH, Glickman LT. Epidemiologic, clinical, pathologic, and prognostic characteristics of splenic hemangiosarcoma and splenic hematoma in dogs: 217 cases (1985). J Am Vet Med Assoc. 1988;193(6):706–12.
CAS
PubMed
Google Scholar
Cleveland MJ, Casale S. Incidence of malignancy and outcomes for dogs undergoing splenectomy for incidentally detected nonruptured splenic nodules or masses: 105 cases (2009–2013). J Am Vet Med Assoc. 2016;248(11):1267–73.
Article
PubMed
Google Scholar
Wendelburg KM, Price LL, Burgess KE, Lyons JA, Lew FH, Berg J. Survival time of dogs with splenic hemangiosarcoma treated by splenectomy with or without adjuvant chemotherapy: 208 cases (2001–2012). J Am Vet Med Assoc. 2015;247(4):393–403.
Article
PubMed
Google Scholar
Marconato L, Chalfon C, Finotello R, Polton G, Vasconi ME, Annoni M, Stefanello D, Mesto P, Capitani O, Agnoli C, et al. Adjuvant anthracycline-based vs metronomic chemotherapy vs no medical treatment for dogs with metastatic splenic hemangiosarcoma: A multi‐institutional retrospective study of the Italian Society of Veterinary Oncology. Veterinary Comparative Oncology. 2019;17(4):537–44.
Article
CAS
PubMed
Google Scholar
Clifford CA, Mackin AJ, Henry CJ. Treatment of canine hemangiosarcoma: 2000 and beyond. J Vet Intern Med. 2000;14(5):479–85.
Article
CAS
PubMed
Google Scholar
Kim SE, Liptak JM, Gall TT, Monteith GJ, Woods JP. Epirubicin in the adjuvant treatment of splenic hemangiosarcoma in dogs: 59 cases (1997–2004). J Am Vet Med Assoc. 2007;231(10):1550–7.
Article
CAS
PubMed
Google Scholar
Gardner HL, London CA, Portela RA, Nguyen S, Rosenberg MP, Klein MK, Clifford C, Thamm DH, Vail DM, Bergman P, et al. Maintenance therapy with toceranib following doxorubicin-based chemotherapy for canine splenic hemangiosarcoma. BMC Vet Res. 2015;11:131.
Article
PubMed
PubMed Central
CAS
Google Scholar
Hammer AS, Couto CG, Filppi J, Getzy D, Shank K. Efficacy and toxicity of VAC chemotherapy (vincristine, doxorubicin, and cyclophosphamide) in dogs with hemangiosarcoma. J Vet Intern Med. 1991;5(3):160–6.
Article
CAS
PubMed
Google Scholar
Alexander CK, Cronin KL, Silver M, Gardner HL, London C. The addition of metronomic chemotherapy does not improve outcome for canine splenic haemangiosarcoma. J Small Anim Pract. 2019;60(1):32–7.
Article
CAS
PubMed
Google Scholar
Finotello R, Stefanello D, Zini E, Marconato L. Comparison of doxorubicin-cyclophosphamide with doxorubicin-dacarbazine for the adjuvant treatment of canine hemangiosarcoma. Vet Comp Oncol. 2017;15(1):25–35.
Article
CAS
PubMed
Google Scholar
Sorenmo KU, Baez JL, Clifford CA, Mauldin E, Overley B, Skorupski K, Bachman R, Samluk M, Shofer F. Efficacy and toxicity of a dose-intensified doxorubicin protocol in canine hemangiosarcoma. J Vet Intern Med. 2004;18(2):209–13.
Article
PubMed
Google Scholar
Khammanivong A, Gorden BH, Frantz AM, Graef AJ, Dickerson EB. Identification of drug-resistant subpopulations in canine hemangiosarcoma. Vet Comp Oncol. 2016;14(3):e113–25.
Article
CAS
PubMed
Google Scholar
Marrington AM, Killick DR, Grant IA, Blackwood L. Toxicity associated with epirubicin treatments in a large case series of dogs. Vet Comp Oncol. 2012;10(2):113–23.
Article
CAS
PubMed
Google Scholar
Williams J, Phillips C, Byrd HM. Factors Which Influence Owners When Deciding to Use Chemotherapy in Terminally Ill Pets. Animals (Basel).2017;7(3):18. Published 2017 Mar 7. https://doi.org/10.3390/ani7030018.
U’Ren LW, Biller BJ, Elmslie RE, Thamm DH, Dow SW. Evaluation of a novel tumor vaccine in dogs with hemangiosarcoma. J Vet Intern Med. 2007;21(1):113–20.
Article
PubMed
Google Scholar
Konduri V, Halpert MM, Baig YC, Coronado R, Rodgers JR, Levitt JM, Cerroni B, Piscoya S, Wilson N, DiBernardi L, et al. Dendritic cell vaccination plus low-dose doxorubicin for the treatment of spontaneous canine hemangiosarcoma. Cancer Gene Ther. 2019;26(9–10):282–91.
Article
CAS
PubMed
PubMed Central
Google Scholar
Yannelli JR, Wouda R, Masterson TJ, Avdiushko MG, Cohen DA. Development of an autologous canine cancer vaccine system for resectable malignant tumors in dogs. Vet Immunol Immunopathol. 2016;182:95–100.
Article
CAS
PubMed
Google Scholar
Crossley RA, Matz A, Dew T, Kalinauskas A, Faucette N, Poff B, Silbart LK, Suckow MA. Safety Evaluation of Autologous Tissue Vaccine Cancer Immunotherapy in a Canine Model. Anticancer Res. 2019;39(4):1699–703.
Article
CAS
PubMed
Google Scholar
Brown BN, Ratner BD, Goodman SB, Amar S, Badylak SF. Macrophage polarization: an opportunity for improved outcomes in biomaterials and regenerative medicine. Biomaterials. 2012;33(15):3792–802.
Article
CAS
PubMed
PubMed Central
Google Scholar
Suckow MA, Hall P, Wolter W, Sailes V, Hiles MC. Use of an extracellular matrix material as a vaccine carrier and adjuvant. Anticancer Res. 2008;28(5A):2529–34.
PubMed
Google Scholar
Suckow MA, Wolter WR, Sailes VT. Inhibition of prostate cancer metastasis by administration of a tissue vaccine. Clin Exp Metastasis. 2008;25(8):913–8.
Article
CAS
PubMed
Google Scholar
Suckow MA, Wolter WR, Pollard M. Prevention of de novo prostate cancer by immunization with tumor-derived vaccines. Cancer Immunol Immunother. 2005;54(6):571–6.
Article
CAS
PubMed
Google Scholar
Suckow MA, Heinrich J, Rosen ED. Tissue vaccines for cancer. Expert Rev Vaccines. 2007;6(6):925–37.
Article
CAS
PubMed
Google Scholar
Disis ML. Mechanism of action of immunotherapy. Semin Oncol. 2014;41(Suppl 5):3–13.
Article
CAS
Google Scholar
Davis BW, Ostrander EA. Domestic dogs and cancer research: a breed-based genomics approach. ILAR J. 2014;55(1):59–68.
Article
CAS
PubMed
PubMed Central
Google Scholar
Schiffman JD, Breen M. Comparative oncology: what dogs and other species can teach us about humans with cancer. Philos Trans R Soc Lond B Biol Sci.2015;370(1673):20140231. https://doi.org/10.1098/rstb.2014.0231.
Addissie S, Klingemann H. Cellular Immunotherapy of Canine Cancer. Vet Sci. 2018;5(4):100. Published 2018 Dec 6. https://doi.org/10.3390/vetsci5040100.
Kaufman HL, Atkins MB, Subedi P, Wu J, Chambers J, Joseph Mattingly T 2nd, Campbell JD, Allen J, Ferris AE, Schilsky RL, et al. The promise of Immuno-oncology: implications for defining the value of cancer treatment. J Immunother Cancer. 2019;7(1):129.
Sambi M, Bagheri L, Szewczuk MR. Current Challenges in Cancer Immunotherapy: Multimodal Approaches to Improve Efficacy and Patient Response Rates. J Oncol. 2019;2019:4508794.
Article
PubMed
PubMed Central
CAS
Google Scholar
Ilkovitch D, Ostrand-Rosenberg S. MHC class II and CD80 tumor cell-based vaccines are potent activators of type 1 CD4 + T lymphocytes provided they do not coexpress invariant chain. Cancer Immunol Immunother. 2004;53(6):525–32.
Article
CAS
PubMed
Google Scholar
Wu C, Liu Y, Zhao Q, Chen G, Chen J, Yan X, Zhou YH, Huang Z. Soluble CD40 ligand-activated human peripheral B cells as surrogated antigen presenting cells: A preliminary approach for anti-HBV immunotherapy. Virol J. 2010;7:370.
Article
CAS
PubMed
PubMed Central
Google Scholar
Vono M, Lin A, Norrby-Teglund A, Koup RA, Liang F, Lore K. Neutrophils acquire the capacity for antigen presentation to memory CD4(+) T cells in vitro and ex vivo. Blood. 2017;129(14):1991–2001.
Article
PubMed
PubMed Central
Google Scholar
Lee OE, Ko YT, Kim EJ, Lee KH, Song YN, Kwon JM, Kim YM, Perez MC, Kang DR. SM: Roles of major histocompatibility complex class II in inducing protective immune responses to influenza vaccination. J Virol. 2014;88(14):7764–75.
Aguilera R, Saffie C, Tittarelli A, Gonzalez FE, Ramirez M, Reyes D, Pereda C, Hevia D, Garcia T, Salazar L, et al. Heat-shock induction of tumor-derived danger signals mediates rapid monocyte differentiation into clinically effective dendritic cells. Clin Cancer Res. 2011;17(8):2474–83.
Article
CAS
PubMed
Google Scholar
Zhai J, Gao W, Zhao L, Gao Z, Jiang X, Lu C. Dendritic cell vaccine with Ag85A enhances anti-colorectal carcinoma immunity. Exp Ther Med. 2018;16(6):5123–9.
CAS
PubMed
PubMed Central
Google Scholar
Zhang C, Wang GX, Zhu B. Application of antigen presenting cell-targeted nanovaccine delivery system in rhabdovirus disease prophylactics using fish as a model organism. J Nanobiotechnology. 2020;18(1):24.
Article
CAS
PubMed
PubMed Central
Google Scholar
Mendonca PHB, da Rocha R, Moraes JBB, LaRocque-de-Freitas IF, Logullo J, Morrot A, Nunes MP, Freire-de-Lima CG, Decote-Ricardo D. Canine Macrophage DH82 Cell Line As a Model to Study Susceptibility to Trypanosoma cruzi Infection. Front Immunol. 2017;8:604.
Article
PubMed
PubMed Central
CAS
Google Scholar
de Charette M, Marabelle A, Houot R. Turning tumour cells into antigen presenting cells: The next step to improve cancer immunotherapy? Eur J Cancer. 2016;68:134–47.
Article
PubMed
CAS
Google Scholar
Bodewes R, Geelhoed-Mieras MM, Heldens JG, Glover J, Lambrecht BN, Fouchier RA, Osterhaus AD, Rimmelzwaan GF. The novel adjuvant CoVaccineHT increases the immunogenicity of cell-culture derived influenza A/H5N1 vaccine and induces the maturation of murine and human dendritic cells in vitro. Vaccine. 2009;27(49):6833–9.
Article
CAS
PubMed
Google Scholar
Zhu J, Paul WE. CD4 T cells: fates, functions, and faults. Blood. 2008;112(5):1557–69.
Article
CAS
PubMed
PubMed Central
Google Scholar
Moore AS, Rassnick KM, Frimberger AE. Evaluation of clinical and histologic factors associated with survival time in dogs with stage II splenic hemangiosarcoma treated by splenectomy and adjuvant chemotherapy: 30 cases (2011–2014). J Am Vet Med Assoc. 2017;251(5):559–65.
Article
PubMed
Google Scholar
Ng CY, Mills JN. Clinical and haematological features of haemangiosarcoma in dogs. Aust Vet J. 1985;62(1):1–4.
Article
CAS
PubMed
Google Scholar
Patten SG, Boston SE, Monteith GJ. Outcome and prognostic factors for dogs with a histological diagnosis of splenic hematoma following splenectomy: 35 cases (2001–2013). Can Vet J. 2016;57(8):842–6.
PubMed
PubMed Central
Google Scholar
Kahn SA, Mullin CM, de Lorimier LP, Burgess KE, Risbon RE, Fred RM 3rd, Drobatz K, Clifford CA. Doxorubicin and deracoxib adjuvant therapy for canine splenic hemangiosarcoma: a pilot study. Can Vet J. 2013;54(3):237–42.
Vail DM, MacEwen EG, Kurzman ID, Dubielzig RR, Helfand SC, Kisseberth WC, London CA, Obradovich JE, Madewell BR, Rodriguez CO Jr, et al. Liposome-encapsulated muramyl tripeptide phosphatidylethanolamine adjuvant immunotherapy for splenic hemangiosarcoma in the dog: a randomized multi-institutional clinical trial. Clin Cancer Res. 1995;1(10):1165–70.
CAS
PubMed
Google Scholar
Phillips BS, Kraegel SA, Simonson E, Madewell BR. Acute reactions in dogs treated with doxorubicin: increased frequency with the use of a generic formulation. J Vet Intern Med. 1998;12(3):171–2.
Article
CAS
PubMed
Google Scholar
Ogilvie GK, Reynolds HA, Richardson RC, Withrow SJ, Norris AM, Henderson RA, Klausner JS, Fowler JD, McCaw D. Phase II evaluation of doxorubicin for treatment of various canine neoplasms. J Am Vet Med Assoc. 1989;195(11):1580–3.
CAS
PubMed
Google Scholar
Sorenmo K, Duda L, Barber L, Cronin K, Sammarco C, Usborne A, Goldschmidt M, Shofer F. Canine hemangiosarcoma treated with standard chemotherapy and minocycline. J Vet Intern Med. 2000;14(4):395–8.
Article
CAS
PubMed
Google Scholar
Ogilvie GK, Richardson RC, Curtis CR, Withrow SJ, Reynolds HA, Norris AM, Henderson RA, Klausner JS, Fowler JD, McCaw D. Acute and short-term toxicoses associated with the administration of doxorubicin to dogs with malignant tumors. J Am Vet Med Assoc. 1989;195(11):1584–7.
CAS
PubMed
Google Scholar
Banco B, Grieco V, Servida F, Giudice C. Sudden death in a dog after doxorubicin chemotherapy. Vet Pathol. 2011;48(5):1035–7.
Article
CAS
PubMed
Google Scholar
Gallay-Lepoutre J, Belanger MC, Nadeau ME. Prospective evaluation of Doppler echocardiography, tissue Doppler imaging and biomarkers measurement for the detection of doxorubicin-induced cardiotoxicity in dogs: A pilot study. Res Vet Sci. 2016;105:153–9.
Article
CAS
PubMed
Google Scholar
Loar AS, Susaneck SJ. Doxorubicin-induced cardiotoxicity in five dogs. Semin Vet Med Surg (Small Anim). 1986;1(1):68–71.
CAS
Google Scholar
Surachetpong SD, Teewasutrakul P, Rungsipipat A. Serial measurements of cardiac troponin I (cTnI) in dogs treated with doxorubicin. Jpn J Vet Res. 2016;64(4):221–33.
PubMed
Google Scholar
Tomlinson CW, Godin DV, Rabkin SW. Adriamycin cardiomyopathy: implications of cellular changes in a canine model with mild impairment of left ventricular function. Biochem Pharmacol. 1985;34(22):4033–41.
Article
CAS
PubMed
Google Scholar
Brockman BK, Taylor VA, Brockman CM. The price of unconditional love: Consumer decision making for high-dollar veterinary care. J Business Res. 2008;61:397–405.
Article
Google Scholar
Grosenbaugh DA, Leard AT, Bergman PJ, Klein MK, Meleo K, Susaneck S, Hess PR, Jankowski MK, Jones PD, Leibman NF, et al. Safety and efficacy of a xenogeneic DNA vaccine encoding for human tyrosinase as adjunctive treatment for oral malignant melanoma in dogs following surgical excision of the primary tumor. Am J Vet Res. 2011;72(12):1631–8.
Article
CAS
PubMed
Google Scholar
Mason NJ, Gnanandarajah JS, Engiles JB, Gray F, Laughlin D, Gaurnier-Hausser A, Wallecha A, Huebner M, Paterson Y. Immunotherapy with a HER2-Targeting Listeria Induces HER2-Specific Immunity and Demonstrates Potential Therapeutic Effects in a Phase I Trial in Canine Osteosarcoma. Clin Cancer Res. 2016;22(17):4380–90.
Article
CAS
PubMed
Google Scholar
Caballero-Banos M, Benitez-Ribas D, Tabera J, Varea S, Vilana R, Bianchi L, Ayuso JR, Pages M, Carrera G, Cuatrecasas M, et al. Phase II randomised trial of autologous tumour lysate dendritic cell plus best supportive care compared with best supportive care in pre-treated advanced colorectal cancer patients. Eur J Cancer. 2016;64:167–74.
Article
PubMed
Google Scholar